WASHINGTON, March 29, 2023 – Yesterday, The ERISA Industry Committee (ERIC) sent letters of support to House and Senate leaders who reintroduced the Telehealth Expansion Act, bipartisan, bicameral legislation making permanent first-dollar coverage of telehealth services for employees enrolled in a high deductible health plan (HDHP) coupled with a health savings account (HSA).
Miscellaneous Archives:
The ERISA Industry Committee Files Reply Brief in Ongoing NJ WARN Act Lawsuit
Washington, D.C., March 28, 2023 – The ERISA Industry Committee (ERIC) today filed a reply brief in its ongoing lawsuit to defeat the amended New Jersey WARN Act on ERISA preemption grounds. This submission concludes the district court briefing process, leaving just under two weeks for a decision to be reached before the amended law’s April 10 effective date.
The ERISA Industry Committee Endorses the Chronic Disease Management Act of 2023
WASHINGTON, DC, March 27, 2023 – In a letter sent today to Senators Tom Carper (D-DE) and John Thune (R-SD), The ERISA Industry Committee (ERIC) applauded the introduction of legislation that will allow employers to cover a limited but critical set of medical needs related to chronic disease management prior to the patient reaching his or her plan deductible.
ERIC Supports Senate Legislation to Hold Hospitals Accountable to Price Transparency Regulations
WASHINGTON, DC, March 24, 2023 – The ERISA Industry Committee (ERIC) issued a letter of support today for the Hospital Transparency Compliance Enforcement Act (S. 468), legislation introduced by Senator John Kennedy (R-LA) that would impose higher fines for hospitals that do not make publicly available the cost of contracted health care services with insurers – holding hospitals accountable to the 2021 Price Transparency Regulations.
Employer Group: Texas HB 2021 Violates Federal Law, Will Raise Health Care Costs, Threatens Employer-Sponsored Health Insurance
Washington, D.C., March 22, 2023 – The ERISA Industry Committee (ERIC) submitted a comment letter to the Texas House Insurance Committee urging members to oppose HB 2021, a bill that would violate federal law by allowing state legislators to interfere with the operation of multi-state employer-sponsored health benefits.
The “Pharmacy Benefit Manager Transparency Act” Does Too Little to Bring Transparency and Accountability to the Prescription Drug Market
WASHINGTON, DC, March 22, 2023 – In a letter sent yesterday to the U.S. Senate Committee on Commerce, Science, and Transportation, The ERISA Industry Committee (ERIC) urged the members to vote no on the Pharmacy Benefit Manager Transparency Act (PBMTA, S. 127), legislation that fails to include employer-focused, comprehensive solutions that would bring clarity and responsibility to the prescription drug supply chain.
The ERISA Industry Committee Refiles Motion for Summary Judgment in NJ WARN Act Lawsuit
Washington, D.C., March 14, 2023 – The ERISA Industry Committee (ERIC) today refiled a motion for summary judgment in its ongoing lawsuit, The ERISA Industry Committee v. Robert Asaro-Angelo, the Commissioner of the New Jersey Department of Labor and Workforce Development. This filing follows the completion of an expedited discovery process ordered by the Court, regarding ERIC’s standing to file the suit.
The ERISA Industry Committee Appoints Melissa Bartlett to Senior Vice President for Health Policy
WASHINGTON, March 2, 2023 – The ERISA Industry Committee (ERIC) announced today that it has appointed Melissa Bartlett as senior vice president for health policy.
The ERISA Industry Committee Opposes SEC “Hard Close” Proposal that Would Create Disadvantages for Retirement Savers
WASHINGTON, February 14, 2023 – The ERISA Industry Committee (ERIC) today submitted comments opposing a U.S. Securities and Exchange Commission (SEC) proposed regulation affecting the operation of most open-end mutual funds.
The ERISA Industry Committee Urges Senate Judiciary Committee to Advance Legislation to Enhance Prescription Drug Competition and Affordability
WASHINGTON, February 8, 2023 – The ERISA Industry Committee (ERIC) urged members of the Senate Committee on the Judiciary in a letter to vote in favor of several bills which would improve transparency, promote competition, and prohibit practices that discourage affordability within the prescription drug market.